Investments

9 Months Ended

Sep. 30, 2022

Investments Debt And Equity Securities [Abstract]

4. INVESTMENTS

Investments consisted of the following (in thousands):


			Gross Unrealized
					Losses
	Amortized				Less than			Greater than			Estimated
September 30, 2022	Cost		Gains		One Year			One Year			Fair Value
Short-term investments:
Available-for-sale securities:
Corporate debt securities	$	135,140	$	—	$	(1,860	)	$	(712	)	$	132,568
U.S. government and agency debt securities		135,444		4		(823	)		(569	)		134,056
Non-U.S. government debt securities		50,148		—		(311	)		(236	)		49,601
Total short-term investments		320,732		4		(2,994	)		(1,517	)		316,225
Long-term investments:
Available-for-sale securities:
Corporate debt securities		87,038		—		(2,757	)		(606	)		83,675
U.S. government and agency debt securities		73,109		—		(1,768	)		(1,374	)		69,967
Non-U.S. government debt securities		12,021		—		—			(555	)		11,466
		172,168		—		(4,525	)		(2,535	)		165,108
Held-to-maturity securities:
Certificates of deposit		1,820		—		—			—			1,820
Total long-term investments		173,988		—		(4,525	)		(2,535	)		166,928
Total investments	$	494,720	$	4	$	(7,519	)	$	(4,052	)	$	483,153

December 31, 2021
Short-term investments:
Available-for-sale securities:
Corporate debt securities	$	85,201	$	177	$	(39	)	$	—		$	85,339
U.S. government and agency debt securities		45,349		35		(24	)		—			45,360
Non-U.S. government debt securities		68,046		75		(53	)		—			68,068
Total short-term investments		198,596		287		(116	)		—			198,767
Long-term investments:
Available-for-sale securities:
Corporate debt securities		111,793		—		(654	)		—			111,139
U.S. government and agency debt securities		81,296		—		(517	)		—			80,779
Non-U.S. government debt securities		35,902		—		(210	)		—			35,692
		228,991		—		(1,381	)		—			227,610
Held-to-maturity securities:
Certificates of deposit		1,820		—		—			—			1,820
Total long-term investments		230,811		—		(1,381	)		—			229,430
Total investments	$	429,407	$	287	$	(1,497	)	$	—		$	428,197

At September 30, 2022, the Company reviewed its investment portfolio to assess whether the unrealized losses on its available-for-sale investments were temporary. Investments with unrealized losses consisted primarily of corporate debt securities and debt securities issued and backed by U.S. agencies and the U.S. government. At September 30, 2022, the aggregate estimated fair value of investments in an unrealized loss position was $477.0 million. The Company has the intent and ability to hold these investments until recovery, which may be at maturity. In making the determination whether the decline in fair value of these securities was temporary, the Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis.

In January 2022, the Company purchased a convertible promissory note in the principal amount of $0.5 million from Synchronicity Pharma, Inc. (“Synchronicity”), a related party. The convertible promissory note was classified as an available-for-sale corporate debt instrument. During the three months ended September 30, 2022, the Company determined there was an other-than-temporary loss related to this investment in Synchronicity and the $0.5 million was

recorded within “Other (expense) income, net” in the accompanying condensed consolidated statements of operations and comprehensive loss.

In May 2014, the Company entered into an agreement to invest in a partnership, Fountain Healthcare Partners II, L.P. of Ireland (“Fountain”), which was created to carry on the business of investing exclusively in companies and businesses engaged in the healthcare, pharmaceutical and life sciences sectors. As of September 30, 2022, the Company’s total contribution in Fountain was equal to €8.0 million, and its commitment represented approximately 7% of the partnership’s total funding. The Company is accounting for its investment in Fountain under the equity method.

During the three months ended March 31, 2022, one of the companies within the Fountain portfolio was acquired by a third party. The Company’s proportional share of the proceeds from this transaction was $1.1 million, of which $1.0 million was received during the three months ended March 31, 2022 and the remaining $0.1 million is being held in escrow until May 2023. The transaction was accounted for under the cumulative earnings approach whereby the return on investment of $0.6 million was recorded as a gain within “Other (expense) income, net” in the accompanying condensed consolidated statements of operations and comprehensive loss and the return of investment of $0.5 million was recorded as a reduction in the Company’s net investment in Fountain. The Company’s net investment in Fountain was $6.7 million and $6.1 million at September 30, 2022 and December 31, 2021, respectively, and was included within “Other assets” in the accompanying condensed consolidated balance sheets.

During the three and nine months ended September 30, 2022, the Company recorded increases of $0.5 million and $1.6 million, respectively, in its investment in Fountain, which represented the Company’s proportional share of Fountain’s net gains.

Realized gains and losses on the sales and maturities of investments, which were identified using the specific identification method, were as follows:


	Nine Months Ended September 30,
(In thousands)	2022		2021
Proceeds from the sales and maturities of investments	$	190,994	$	239,228
Realized gains	$	—	$	34
Realized losses	$	529	$	977

The Company’s available-for-sale and held-to-maturity securities at September 30, 2022 had contractual maturities in the following periods:


	Available-for-sale				Held-to-maturity
	Amortized		Estimated		Amortized		Estimated
(In thousands)	Cost		Fair Value		Cost		Fair Value
Within 1 year	$	318,866	$	314,355	$	1,820	$	1,820
After 1 year through 5 years		174,034		166,978		—		—
Total	$	492,900	$	481,333	$	1,820	$	1,820